Financial factsheet
Q1 2026
October 1, 2025 - December 31, 2025
SCHOTT Pharma
Results of operations (in EUR m / in %) | Q1 2026 | Q1 2025 |
Revenue | 240.2 | 231.4 |
Revenue growth at constant currencies | +4.8% | +4.8% |
High-value solutions (HVS) revenue share | 57% | 55% |
EBITDA | 65.2 | 58.7 |
EBITDA margin | 27.1% | 25.4% |
EBIT | 43.8 | 40.2 |
EBIT margin | 18.2% | 17.4% |
Financial result | -1.8 | -3.4 |
Income tax expenses | -8.8 | -7.0 |
Profit for the period | 33.3 | 29.8 |
Earnings per share (in EUR) | 0.22 | 0.20 |
Financial position (in EUR m) | Q1 2026 | Q1 2025 |
Cash flows from operating activities | 3.4 | 25.1 |
Cash flows from ongoing investing activities | -23.2 | -21.0 |
Free cash flow | -19.8 | 4.1 |
Net assets (in EUR m / in %) | Dec. 31, 2025 | Sep. 30, 2025 |
Working capital | 244.1 | 199.3 |
Working capital in % of revenue | 25.4% | 20.2% |
Equity ratio | 57.3% | 55.9% |
Net debt | 146.9 | 122.2 |
Employees | Dec. 31, 2025 | Sep. 30, 2025 |
Revenue bridge
(in EUR m)
+4.8%
-1.0%
+3.8%
-2.4
240.2
231.4
+11.2
Q1 2025 Organic growth FX Q1 2026
Revenue by region
(in EUR m)
HVS revenue share
Q1 2026
(in %)
22.2
43.2
37.8
Q1 2026
137.0
43%
57%
EMEA APAC137.2
EBITDA margin EBIT
EBIT margin
24.3%
24.1
17.6%
21.9%
19.0
14.8%
Q1 2025 Organic growth
FX
Q1 2026
Drug Delivery Systems (DDS)
Revenue bridge
(in EUR m)
+12.1
128.3
(in EUR m)
-3.2
103.1 | -0.9 | +0.8 | 103.1 | EBIT margin | 20.0% | 25.1% |
Q1 2025 | Organic growth | FX | Q1 2026 |
HVS Core
Headcount (as of the reporting date) | 4,829 | 4,811 | ||
Drug Containment Solutions (DCS) | ||||
Revenue bridge | Results of operations (in EUR m / in %) | Q1 2026 | Q1 2025 | |
+9.4% -2.5% +6.9% Revenue 137.2 128.3 EBITDA 33.4 28.1 | ||||
Results of operations (in EUR m / in %) Q1 2026 Q1 2025 | |||||
-0.8% | +0.8% | -0.0% | Revenue | 103.1 | 103.1 |
EBITDA | 32.6 | 35.1 | |||
EBITDA margin | 31.6% | 34.1% | |||
EBIT | 20.7 | 25.9 | |||